Guggenheim started coverage on shares of Nautilus Biotechnology (NASDAQ:NAUT – Free Report) in a research report released on Thursday, Marketbeat.com reports. The brokerage issued a buy rating and a $6.00 price objective on the stock.
Separately, Jefferies Financial Group began coverage on shares of Nautilus Biotechnology in a research report on Monday, June 3rd. They issued a hold rating and a $3.00 price target for the company.
Get Our Latest Stock Analysis on Nautilus Biotechnology
Nautilus Biotechnology Stock Performance
Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) last announced its quarterly earnings data on Tuesday, April 30th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. As a group, equities analysts forecast that Nautilus Biotechnology will post -0.68 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in NAUT. Federated Hermes Inc. bought a new stake in Nautilus Biotechnology during the third quarter worth about $29,000. Presidio Capital Management LLC bought a new stake in shares of Nautilus Biotechnology during the fourth quarter valued at approximately $30,000. Axxcess Wealth Management LLC bought a new stake in shares of Nautilus Biotechnology during the fourth quarter valued at approximately $30,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Nautilus Biotechnology by 351.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,452 shares of the company’s stock valued at $43,000 after purchasing an additional 11,248 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Nautilus Biotechnology by 35.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 16,078 shares of the company’s stock valued at $48,000 after purchasing an additional 4,239 shares during the last quarter. Institutional investors and hedge funds own 50.71% of the company’s stock.
About Nautilus Biotechnology
Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
Further Reading
- Five stocks we like better than Nautilus Biotechnology
- What Investors Need to Know to Beat the Market
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- MarketBeat Week in Review – 6/24 – 6/28
- What Are the FAANG Stocks and Are They Good Investments?
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.